August 2016 – Page 5

AUG 23, 2016 – Bruce Japsen

As Aetna AET -0.37% and UnitedHealth Group UNH -1.17% retreat next year from most public exchanges under the Affordable Care Act in the face of losses they say they can’t handle, a model is emerging in Florida that may be the answer to caring for patients and turning a profit.

Florida Blue, a Blue Cross and Blue Shield plan, is offering a diverse mix of products statewide on public exchanges. That is in sharp contrast to UnitedHealth and Aetna, two of the nation’s largest health insurers, which will leave public exchanges in most states–including Florida beginning in 2017.

“ Florida Blue offers every metal level ACA product in every county in the state , and we offer four different product networks to satisfy a full range of consumer needs, so the makeup of the plans our members have chosen is very mixed,” Florida Blue spokesman Paul Kluding said in an interview.

Florida Blue said it began to prepare for Obamacare patients and their expensive medical claims three years ago when the rollout of coverage was dogged by technical issues of the Healthcare.gov web site. Back then, Florida Blue opened 20 retail centers across the state to sign up residents and the investment paid off.

READ THE REST HERE

virtual-simulations-4-operating-theatre-and-surgeons-1200x674.jpg

SOMERVILLE, N.J., Aug. 24, 2016 /PRNewswire-USNewswire/ — Ethicon, Inc., part of the Johnson & Johnson Medical Devices Companies, announces a strategic collaboration with Touch Surgery to help improve patient outcomes by delivering simulated surgical training based on the safe and efficacious use of Ethicon products in a free mobile app that can reach medical professionals in even remote regions of the world.

Ethicon’s more than 60-year history in educating surgeons and deep expertise with surgical products, combined with Touch Surgery’s technology platform and unique 3D simulations, will provide digital content that aids surgeons and students in training anytime, anywhere.

A report on global surgery, commissioned in 2015 by The Lancet, found nearly one-third of the global burden of disease can be treated surgically and that five billion people lack access to safe and affordable surgical care.¹

“We’re looking to improve the standards of surgical care and treatment around the world, accelerating our pace of innovation and aiding the training of more physicians through collaborations such as this agreement with Touch Surgery,” says Michael del Prado, Company Group Chairman, Ethicon. “It reflects our broad-based approach to innovation and is another important step toward developing a trusted education ecosystem that improves patient outcomes.”

The Touch Surgery platform empowers and connects the global surgery community by enabling virtual surgical training on procedures in 3-D operating room simulations that are unlike other available solutions. The app currently has one million users and helps enable surgeons and other healthcare providers to practice more than 75 procedures of varying surgical specialties.

Ethicon and Johnson & Johnson Medical Device Companies are committed to expanding access to surgical procedures around the world, especially in developing countries where access to the latest training practices can be limited. The collaboration with Touch Surgery will help bolster the library of procedures to create leading educational content across a broad range of surgical specialties, helping to expand resident education and standardize procedures.

Ethicon will begin by addressing training needs in General Surgery and will look at potential opportunities to expand over time to include other Johnson & Johnson Medical Device Companies businesses and specialties, such as orthopaedics and cardiovascular.

About Ethicon
From creating the first sutures, to revolutionizing surgery with minimally invasive procedures, Ethicon has made significant contributions to surgery for more than 60 years. Through Ethicon’s surgical technologies and solutions including sutures, staplers, energy devices, trocars and hemostats and our commitment to treating serious medical conditions like obesity and cancer worldwide, we deliver innovation to make a life-changing impact. Learn more at www.ethicon.com, and follow us on Twitter @Ethicon. Ethicon represents the products and services of Ethicon, Inc. (the signing party) and certain of their affiliates.

About Johnson & Johnson Medical Devices
Having made significant contributions to surgery for more than a century, the Johnson & Johnson Medical Devices Companies are in the business of reaching more patients and restoring more lives. The group represents the most comprehensive surgical technology and specialty solutions business in the world, offering an unparalleled breadth of products, services, programs and research and development capabilities directed at advancing patient care while delivering clinical and economic value to health care systems worldwide.

¹The Lancet Commission on Global Surgery, 2015,http://www.who.int/hrh/news/2015/lancet_commission_globsurgery/en/

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to a new collaboration to expand access to digital training in surgical procedures. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Ethicon, Inc., any of the other Johnson & Johnson Medical Devices Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; uncertainty of success and continued use of the app; competition, including technological advances, new products and patents attained by competitors; changes in behavior and spending patterns of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Johnson & Johnson Medical Devices Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

MEDIA CONTACTS:
Peggy Ballman
Mobile: 908-310-7721
pballman@its.jnj.com

SOURCE Ethicon

Related Links

http://www.ethicon.com

August 18, 2016 – by Carlos Correa

SAN DIEGO – A robot created to help surgeons during complicated procedures is bringing new hope to young patients who suffer neurological disorders.

Rady Children’s Hospital is among the few in the country using the technology.

The Rosa Robot has two main parts – a computer brain and a robotic arm. It allows surgeons to create a 3D map of a patient’s brain.

“I think for the future of epilepsy centers and any center that wants to treat epilepsy in the future, this is a vital importance. Rady Children’s is one of the first five hospitals in the country to get this robotic technology to enable us to do that and its important in leading the field for it and continue to treating epilepsy in the best way possible,” said Dr. David Gonda, director of surgical epilepsy, Rady Children’s Hospital.

Rosa is a robotized surgical assistant – the most advanced of its kind.

It’s one of a few being used across the country and six months ago it arrived here at Rady Children’s hospital.

So, far its helped about twenty patients.

Through the robot, doctors are able to look at a 3D image from any angle and at any depth.

READ THE REST HERE

CARLSBAD, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) — Alphatec Holdings, Inc. (ATEC), the parent company of Alphatec Spine, Inc., a global provider of spinal fusion technologies, today announced the effectiveness of a one-for-twelve reverse stock split of its common stock. The reverse stock split will take effect at 5:00 pm Eastern Time on August 24, 2016 and the Company’s common stock will open for trading on The NASDAQ Global Select Market on August 25, 2016 on a post-split basis.

The reverse stock split is intended to increase the per share trading price of the Company’s common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Global Select Market. As a result of the reverse stock split, every twelve shares of the Company’s common stock issued and outstanding prior to the opening of trading on August 25, 2016 will be consolidated into one issued and outstanding share. No fractional shares are being issued in connection with the reverse stock split. Stockholders who would otherwise hold a fractional share of common stock will receive a cash payment in lieu of such fractional share. In connection with the reverse stock split, there will be no change in the nominal par value per share of $0.0001.

Trading of the Company’s common stock on The NASDAQ Global Select Market will continue, on a split-adjusted basis, with the opening of the markets on Thursday, August 25, 2016, under the existing trading symbol “ATEC” but with a new CUSIP number 02081G 201. The reverse stock split reduces the number of shares of the Company’s common stock outstanding from approximately 102.5 million pre-reverse split shares to approximately 8.5 million post-reverse split shares.

The Company has retained its transfer agent, Computershare Trust Company, N.A. (“Computershare”), to act as its exchange agent for the reverse split. Computershare will provide stockholders of record as of the effective date of the reverse stock split a letter of transmittal providing instructions for the exchange of their physical certificates. Stockholders owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers’ particular processes, and will not be required to take any action in connection with the reverse stock split.

The reverse stock split was approved within a range of one-for-four to one-for-twelve by the Company’s stockholders at the 2016 Annual Meeting of Stockholders held on August 18, 2016, and the specific ratio of one-for-twelve was approved by the Company’s Board of Directors. For more information regarding the reverse stock split, please refer to the Company’s definitive proxy statement filed with the Securities and Exchange Commission on Schedule 14-A on June 22, 2016.

About Alphatec Spine

Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings, Inc. (ATEC), is a global medical device company that designs, develops, manufactures and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities and trauma. The Company’s mission is to improve lives by delivering advancements in spinal fusion technologies. The Company and its affiliates market products in the U.S. and internationally via a direct sales force and independent distributors.

Additional information can be found at www.alphatecspine.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the reverse stock split of the Company’s common stock and its intended purpose. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. These risks and uncertainties include, among other things, the factors discussed under the heading “Risk Factors” contained in the Company’s annual report and quarterly reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company disclaims any obligation to update the information contained in this press release as new information becomes available.

Contact:

Investor/Media Contact:
Christine Zedelmayer 
Investor Relations 
Alphatec Spine, Inc. 
(760) 494-6610
czedelmayer@alphatecspine.com

TORONTO, ON–(Marketwired – August 24, 2016) – Titan Medical Inc. (TMD.TO) (TITXF) today announced that it extended the rights granted to Longtai Medical Inc. to negotiate an exclusive marketing, sales and distribution agreement for Titan’s SPORT™ Surgical System in the Asia Pacific Region. The parties have agreed to modify their previous three-month extension to monthly progress reviews. The granting of exclusive rights to negotiate a distribution agreement continues to be part of the Letter Agreement with Longtai Medical Inc.

About Titan Medical Inc.

Titan Medical Inc. is a Canadian public company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”). The Company’s SPORT™ Surgical System, currently under development, includes a surgeon-controlled robotic platform that incorporates a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures through a single incision. The surgical system also includes a surgeon workstation that provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and provides a 3D high-definition endoscopic view of inside a patient’s body. The SPORT™ Surgical System is designed to enable surgeons to perform a broad set of surgical procedures for general abdominal, gynecologic, and urologic indications. For more information, visit the Company’s website at www.titanmedicalinc.com.

About Longtai Medical Inc. and Ningbo Long Hengtai International Trade Co. Ltd.

Longtai is a British Columbia corporation associated with Ningbo Long Hengtai International Trade Co. Ltd., a corporation engaged in the distribution of medical devices and related products in China. Longtai is owned by one or more individuals and Shiguang Ling, Chairman of Ningbo Long Hengtai International Trade Co. Ltd.

Ningbo Long Hengtai International Trade Co. Ltd. is engaged in the distribution of medical equipment in China through a substantial network of sub dealers and serves a number of medical device companies including a leading European provider of diagnostic imaging and healthcare IT solutions for hospitals and care centers around the world.

Forward-Looking Statements

This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 30, 2016 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

By Joe Carlson – August 25, 2016

Medtronic PLC on Thursday reported lower adjusted net income in the most recent quarter and reiterated sales expectations for the year.

The company’s adjusted profit amounted to $1.03 in diluted earnings per share, two cents above Wall Street forecasts. Revenue was nearly in line with what had been expected.

Medtronic shares fell about 1 percent in early morning trading.

Analysts with Leerink Partners predicted that Medtronic’s stock performance would be affected by the generally high expectations among investors in the med-tech sector overall this quarter.

Investors on the earnings call Thursday asked about the timing of Medtronic’s announcement Tuesday that it had completed its $1.1 billion acquisition of HeartWare, whose high-end heart pumps treat advanced heart failure by helping pump blood through the body. The HeartWare deal was originally projected to close by October.

“We really felt that we were in a position where we were getting critical mass around our expertise in heart failure,” chief executive Omar Ishrak said. “Where HeartWare was positioned as a company, we felt that we could add immediate value … We felt that this was absolutely the right time.”

READ THE REST HERE

SAN JOSE, Calif., Aug. 24, 2016 /PRNewswire/ — SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System^® (“iFuse”), a patented triangular-shaped minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, announced the publication of two-year results from INSITE (Investigation of Sacroiliac Fusion Treatment – NCT01681004) a landmark prospective, multicenter, randomized controlled trial (RCT) of MIS SI joint fusion with iFuse compared to non-surgical management (NSM). Results of this Level 1, high quality study were published in the International Journal of Spine Surgery titled: Two-Year Outcomes from a Randomized Controlled Trial of Minimally Invasive Sacroiliac Joint Fusion vs. Non-Surgical Management for Sacroiliac Joint Dysfunction¹. The study showed that rapid improvements in pain, disability and quality of life for the iFuse group were larger than those seen for the NSM group and were durable to two years. This large, Level 1 RCT adds to the more than 40 peer-reviewed publications on iFuse and further reinforces positive outcomes and product durability demonstrated in previously reported 3 year, 4.5 year and 5 year publications.^2-4

148 subjects were enrolled, randomized 2:1 (102 iFuse/46 NSM), and treated at 19 centers in the United States including both private practice and academic institutions. In the iFuse group, the mean SI joint pain score improved from 82.3 at baseline to 30.1 at 6 months, 28.6 at 12 months and 26.7 at two years, corresponding to improvements from baseline of 52.3, 53.7 and 55.4 points, respectively (all p<.0001, Figure 1). Disability, as measured using the Oswestry Disability Index (ODI), decreased from a mean 57.2 at baseline to 29.9, 28.3 and 28.7 at months 6, 12 and 24, representing mean improvements of 27.4, 28.9 and 28.4 points, respectively (p<.0001)

The revision surgery rate was low at 3.4% (3/89) consistent with previously reported long-term results for iFuse^2,5 and roughly one-third that for lumbar fusion surgery⁶. Two-year results also showed a 29.7% decrease from baseline in the number of study subjects taking opioids (Figure 2) which is consistent with a 28% reduction in opioid use observed in a previously reported prospective multicenter two-year study⁵.

“These two-year results from the INSITE study illustrate the durability of SI joint fusion with iFuse and further validate previously reported 6- and 12-month results that showed rapid improvement in pain, function and quality of life in this highly debilitated patient population,” said Frank Phillips, MD of Rush University Medial Center in Chicago, IL. “This positive publication validates the consistency of the earlier publications on iFuse and will hopefully encourage health plans across the U.S. to establish coverage for this effective procedure.”

About SI-BONE, Inc.
SI-BONE, Inc. (San Jose, California) is a leading sacroiliac joint medical device company dedicated to the development of tools and products for patients with low back issues related to certain SI joint disorders. The company develops, manufactures and markets minimally invasive products for the SI joint. SI-BONE, Inc. received original 510(k) clearance in November 2008 from the Food and Drug Administration (FDA) to market its iFuse Implant System. The CE mark for European commercialization was obtained in November 2010.

MORRISTOWN, N.J., Aug. 24, 2016 /PRNewswire/ — Tyber Medical, a privately held company focused on developing innovative medical devices for private label opportunities and advancing the science of bioengineered surfaces, announces the commercial launch of their lateral plating system.

Tyber Medical is excited to announce a product portfolio expansion with a low profile lateral plate including an innovative fixation technology. Through the use of new and patented features, the implant provides three points of fixation in each vertebral body, eliminating some instrumentation required by other systems on the market while minimizing surgical steps. In addition, to reduce the possibility of neurologic deficit, the elegant design of the screw mates it flush with the surface of the plate when locked. The result is potentially the best fixation option available.

“The market for lateral access instruments and implants is one of the fastest growing segments. Companies that haven’t already secured their share of the market will soon find it harder and harder to compete. This new lateral plating system, together with Tyber’s lateral retractor and interbody product, creates one of the best lateral access systems available in the market today,” said Steve Zeiger, Senior Director of Sales and Marketing at Tyber Medical.

According to multiple market research sources, the global market for minimally invasive surgery is forecast to grow faster than any other segment over the next 3 – 5 years. Further, in todays OR, the posterior lumbar business goes hand in hand with the lateral business. The launch of Tyber Medical’s competitive lateral implant, complete with a lateral plating system, is very timely considering the inflection point the market is approaching where the utilization of other approaches to the lumbar spine is reported to be stabilizing or even shrinking.

About Tyber Medical:

Tyber Medical, LLC, Morristown, New Jersey, a rapid commercialization device company, is creating new pathways to regulatory approved bioengineered implants and instruments for orthopedic companies, large distributors, and hospital organizations. Tyber Medical designs and develops full class II orthopedic systems; verifies and validates those systems using a QSR and ISO 13485 certified quality system; and pursues and maintains both US (FDA 510k) and OUS (CE Mark) regulatory approvals. Current products include the opening osteotomy system, headless and headed compression screws, snap-off screws, cervical plating system, lateral retractor system and spinal interbody spacers featuring both standard sterile and non-sterile PEEK andTyPEEK^®, a proprietary titanium plasma sprayed PEEK. The company is also developing BioTy™, a nanotopography surface modification which limits the adherence of bacteria to implants. For more information, please visit www.tybermedical.com.

The TyWedge™ System and Spinal Interbody Spacers are made with PEEK-OPTIMA^® from Invibio^® Biomaterial Solutions.

Contact:
Steve Zeiger
89 Headquarters Plaza North, #1464
Morristown, New Jersey 07960
(866) 761-0933
szeiger@tybermed.com

SOURCE Tyber Medical, LLC

Related Links

http://www.tybermedical.com

08/23/2016

CTL Medical Corporation, a Dallas-based medical device manufacturing and service company, announced that it has established a General Services Administration partnership with Firehouse Medical Inc. to sell its line of innovative spinal implants and devices to the U.S. government. GSA contracts allow commercial companies to establish long-term, government-wide contracts and sell their products and services at volume discount pricing.

“Partnering with Firehouse Medical Inc. was a no-brainer for us. Their extensive experience working with the U.S. government is something we value, and we are thrilled to provide our products to a new customer base,” said Daniel Chon, president and CEO of CTL Medical Corporation.

Firehouse Medical Inc. is a full line distributor of medical/rescue supplies and training simulators, currently holding three long-term, fixed-price GSA contracts; a Defensive Logistics Agency Med/Surgical contract; a Distribution and Pricing Agreement with the DLA; and multiple state contracts.

“We are extremely pleased to enter into a partnership with CTL Medical Corporation,” said Brent Poole, CEO of Firehouse Medical Inc. “Because of our multiple GSA contracts, VA hospital relationships and the value of CTL Medical Corporation’s product offerings, we expect to see excellent sales penetration in the government markets we serve.”

For more information on CTL Medical Corporation visit www.ctlmed.com. For more information on Firehouse Medical Inc. visit www.firehousemedical.com.

About CTL Medical Corporation

CTL Medical Corporation was established in 2015 by Daniel Chon, former president & CEO of AccelSPINE®, with the vision of creating a fully integrated, industry leading, global medical device design, development, and manufacturing company. CTL has assembled a world-class executive team, bringing together some of the industry’s most exceptional talent, further extending their position as a leader in medical device design and manufacturing.For more information on CTL Medical Corporation visit www.ctlmed.com.

About Firehouse Medical Inc.

Founded in 1995, Firehouse Medical Inc. and its subsidiary, FHM EMS Supply LLC, are headquartered in Southern California, with sales and warehousing in Huntsville, Alabama. Firehouse Medical Inc. holds three long-term, fixed-price General Services Administration contracts, a Defense Logistics Agency Med/Surgery contract, a Distribution and Pricing Agreement with the DLA, and multiple state contracts. Firehouse Medical consistently ranks in the top 200 GSA contractors in sales performance out of a total of 22,000 GSA contracting companies. For more information on Firehouse Medical Inc. visit http://www.firehousemedical.com.

Media Contact:

Jeff Cheatham

TrizCom PR

O: 972-247-1369

C: 972-961-6171

jeffc@trizcom.com

Like Submit Press Release 123 on Facebook

The post CTL Medical Enters GSA Partnership With Firehouse Medical, Inc. appeared first on Business Press Release Service Distribution | Submit123PR.

SALT LAKE CITY, UT–(Marketwired – Aug 24, 2016) – Amedica Corporation ( NASDAQ : AMDA ), an innovative biomaterial company that develops and commercializes silicon nitride as a platform for biomedical applications, is pleased to announce the U.S. Food and Drug Administration (FDA) clearance of expanded Valeo^® II Lateral Lumbar sizes. The additional sizes of the Valeo II LL interbody fusion device will be commercially available August 29, 2016.

The Valeo II LL interbody fusion device is made entirely of Amedica’s proprietary medical grade silicon nitride ceramic — an ideal material for fusion, due to its inherent osteoconductivity, anti-infective properties, bone-like imaging (artifact-free & radiotranslucent), and exceptional strength. The system includes second generation instrumentation to improve patient safety and surgeon ease of use.

“I’m delighted to announce the recent FDA clearance of our expanded silicon nitride lateral lumbar implant offerings,” said Dr. Sonny Bal, Chairman and Chief Executive Officer. “It’s estimated that lateral lumbar procedures will remain one of the fastest growing interbody fusion segments over the next five years. The minimally invasive nature of the procedure provides patients with benefits such as less blood loss, smaller incisions and shorter hospital and intraoperative times. We believe these clinical benefits, coupled with our unique silicon nitride biomaterial will lead to an improved continuum of care for individuals.”

The recently cleared sizes allow for greater accommodation for a wide range of patient anatomies as well as greater stability as the shape of the implant distributes weight over a larger surface area. The design of the interbody fusion device consists of aggressive teeth for expulsion resistance, knurls for added stability, a threaded insertion feature for precision implant control, and two central cavities maximized for optimal bone graft packing.

The Valeo II LL is indicated for intervertebral body fusion of the spine in skeletally mature patients and is designed for use with autograft to facilitate fusion. Additional information about Amedica’s complete line of products can be found atwww.amedica.com.

About Amedica Corporation
Amedica is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty as well as dental applications. The Company’s products are manufactured in its ISO 13485 certified manufacturing facility and through its partnership with Kyocera, one of the world’s largest ceramic manufacturers. Amedica’s FDA-cleared and CE-marked spine products are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM and private label partnerships.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated within this press release. A discussion of those risks and uncertainties can be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 23, 2016, and in Amedica’s other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

Newer Posts

Older Posts

Search

3 days / 6 sessions
Current Issues in Spine

How A Blue Cross Plan Beat Aetna And UnitedHealth In Obamacare

Ethicon Announces Strategic Collaboration With Touch Surgery To Evolve Medical Education

Rosa Robot provides surgical assistance at Rady Children’s Hospital

Alphatec Holdings Announces One-for-Twelve Reverse Stock Split

Titan Medical Extends Negotiating Period With Longtai Medical Inc.

Medtronic beats forecasts on earnings, despite lower net income

SI-BONE, Inc. Announces Two-Year Results from a Randomized Controlled Trial

Tyber Medical Launches Lateral Plate

CTL Medical Enters GSA Partnership With Firehouse Medical, Inc.

Amedica Receives FDA Clearance for Additional Valeo(R) II Lateral Lumbar Interbody Fusion Device Offerings

STAR Ankle Joint Replacements Last Long Term and Provide Relief for Patients

Medacta USA’s Spine Division Begins 2017 with Key Appointment, Significant Growth

Spinal Stabilization Technologies Announces Start of LOPAIN 2 Clinical Trial in South America for Lumbar Degenerative Disc Disease

$250K Pediatric Device Competition Now Accepting Proposals

First Single-Use Rigid Endoscope to be Demonstrated at AAOS